- NeuroPace (NPCE, Financial) shares plummeted 24% following disappointing NAUTILUS study results.
- Analysts see potential upside with an average target price of $17.83, implying a 43.01% increase from current levels.
- GuruFocus' GF Value suggests a potential downside from the current price, highlighting investment risks.
NeuroPace (NAS: NPCE) witnessed a notable decline of approximately 24% in premarket trading. This followed the company's announcement that its NAUTILUS study did not meet the primary effectiveness objective for the RNS System aimed at treating idiopathic generalized epilepsy. However, there was a silver lining as the device demonstrated positive outcomes in a specific patient subgroup characterized by a lower frequency of seizures.
Wall Street Analysts' Forecasts
According to insights from six analysts, the average one-year price target for NeuroPace Inc (NPCE, Financial) stands at $17.83. This reflects a high estimate of $20.00 and a low of $17.00. These projections signal a potential upside of 43.01% from the current trading price of $12.47. For a more in-depth analysis, you can visit the NeuroPace Inc (NPCE) Forecast page.
The consensus from seven brokerage firms regarding NeuroPace Inc (NPCE, Financial) assigns an average rating of 1.7, which corresponds to an "Outperform" status. This rating scale ranges from 1 (Strong Buy) to 5 (Sell), indicating a generally positive outlook from analysts.
Examining further through GuruFocus metrics, the projected GF Value for NeuroPace Inc over the next year is estimated at $8.89. This suggests a potential downside of 28.71% from the current price of $12.47. The GF Value is GuruFocus' estimate of fair trading value, derived from historical trading multiples, business growth patterns, and future performance forecasts. For comprehensive data, please refer to the NeuroPace Inc (NPCE, Financial) Summary page.
